37^th World Congress on Pharmacology October 31-01, 2024 Amsterdam, Netherlands

Biography:

Lizeth Vargas-Nuñez is a biologist currently pursuing a master’s degree in Basic Biomedical Sciences at the Industrial University of Santander. Building upon her undergraduate studies in biology, she is now immersed in the intricate world of pharmacology and neuroscience. Her research focuses on elucidating the mechanisms underlying levofloxacin- induced peripheral neuropathy in a Wistar rat model. By understanding these mechanisms, she aims to contribute to the development of strategies to mitigate or prevent this adverse drug reaction.

Abstract:

Fluoroquinolone antibiotics are widely used to treat infections of the urinary, respiratory, and gastrointestinal tracts. Despite their efficacy, these drugs have been associated with several clinically significant adverse effects, including tendinopathy and peripheral neuropathy. Levofloxacin, a fluoroquinolone, is particularly linked to a high incidence of peripheral neuropathy, characterized by numbness, pain, loss of reflexes, and hyperesthesia. Notably, the specific mechanisms underlying levofloxacin-induced peripheral neuropathy remain poorly understood. The purpose of this study is to evaluate levofloxacin-induced nociceptive alterations aiming to establish a preclinical Wistar rat model of peripheral neuropathy for testing protective strategies.
 

Biography:

Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. He also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology. His research background is in maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complementary and Alternative medicine is another area of interest.

Abstract:

Asthma is considered to be primarily an inflammatory disorder with secondary bronchoconstriction. Patient manifestations usually are shortness of breath, wheezing, cough and chest tightness. The intensity may vary over time and become exacerbated with external factors that further irritate the airway.While bronchial hyperactivity and airway inflammation may likely be present they are not the only factors that determine diagnosis. Identification of external and other factors that exacerbate asthma is crucial and smoking is also a modifiable factor.High risk patients including geriatric and pediatric patients may require more aggressive treatment.The long term goals of management are to achieve long term symptomatic relief which may include the use of prophylactic agents. Management of asthma initially supported the use of a short acting bronchodilator and prophylactic management where deemed necessary.The categories of asthma medications include controller, reliever, prophylactic and add-on medications.

Biography:

Beom Su Jang has his expertise in evaluation of pharmacokinetic property of noble drug using radioisotope and nuclear imaging. Byeong yong Yoo has his expertise in application of accelerator mass spectrometry. They develop the new RI-ADME evaluation approaches based on accelerator mass spectrometry creates more powerful tools for improving C-14 analysis. They have built this model after years of experience in research, evaluation. The IAEA Coordinated Research Project (CRP): D52043.Depletion of Veterinary Pharmaceuticals and Radiometric Analysis of their Residues in Animal Matrices’ support this study.

Abstract:

The presence of veterinary pharmaceutical residue in animal matrices for food is a major concern from a public health. Such hazards (residues) must be regulated through establishment of national or internationally acceptable regulatory standards and guidelines. Maximum residue limits (MRL): the maximum concentration of residue resulting from use of a veterinary drug that is acceptable in a food is well established as an international guideline, Currently accelerator mass spectrometry is well established with the highest sensitivity for the analyze of C-14 in the samples. Meanwhile recent evidence indicates that humans constantly exposed the antibiotics from livestock; however, whether these contaminants pose a substantial risk to human health is far from understood. The lack of crucial data on exposure and hazard repꠓresents key knowledge gaps that need to be addressed to move forward. Regulation is necessary and to establish internationally acceptable standards/guidelines, scientificaly reliable data from depletion studies and associated analytical methods are required.

For the development of amoxicillin-depletion study, we propose a RI-ADME study using accelerator mass spectrometry for the assessment of the long half life radioisotopes such as C-14/H-3.

Also we propose the nuclear imaging using SPECT for gamma emmiting radioisotopes and PET uses radiotracers that produce positrons. These advenced RI-ADME procedures could applied for the biologics more easily.

Biography:

Bhupendra Prajapati is a Professor in Department of Pharmaceutics, Shree S K Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India and Adjunct Professor Silpakorn University, Thailand. He has 22 years of academic and research experience and published more than 250 researches and review works in international and national Journals. He has delivered invited scientific talk in many conference and seminar worldwide. He authored 150 book chapters in the field of novel drug delivery. He edited 20 books with publishers like Elsevier, AAP CRC, Wiley, Springer and Jenny Stanford. He is a reviewer in many high impact journals and is on the editorial board member.

Abstract:

Statement of the Problem: Cryptococcal meningitis is a fungal infection which mainly impacts the membrane enveloping the brain and spinal cord. Voriconazole is known to have promising therapeutic agent for treatment of fungal infection which is commercially available in both oral and intravenous administrations. In this study, the voriconazole-loaded nanoemulsion formation was developed with the aim to enhance the brain delivery via nasal administration for the treatment of cryptococcal meningitis.

Methodology and Theoretical Orientation: The selection of optimal composition of Oleic acid, Tween 80 and Transcutol P as oil phase, surfactant, and co-surfactant was performed using pseudo-ternary phase diagrams. The results of physicochemical characterization showed that the selected formulations exhibited small droplet size, low polydispersity, adequate zeta potential, etc.

Biography:

Ahmed A Sedik, An assistant Professor of Pharmacology, working at Medical Research and Clinical Studies Institute, National Research Centre, Egypt. He has earned my master and PhD studies from Cairo University at 2016 and 2020, respectively. Nowadays; he had more than 20 innovative scientific publications in highly cited journals and shared in more than 7 national and international projects. He have earned a scholarship from Campus France as a Post- doctoral Researcher, Université Clermont Auvergne, France from 1October 2024 to 3 April 2025 

Abstract:

Potassium dichromate (PD) is an environmental xenobiotic commonly recognized as teratogenic, carcinogenic, and mutagenic in animals and humans. The present study was conducted to investigate the role of tangeretin (TNG) as a neuro-protective drug against PD-induced brain injury in rats. Thirty-two male adult Wistar rats were blindly divided into four groups (8 rats/group). The first group received saline intranasally (i.n.). The second group received a single dose of PD (2 mg/kg, i.n.). The third group received TNG (50 mg/kg; orally), for 14 days followed by i.n. of PD on the last day of the experiment. The fourth group received TNG (100 mg/kg; orally) for 14 days followed by i.n. of PD on the last day of the experiment. Behavioral indices were evaluated 18 h after PD administration. Neuro-biochemical indices and histopathological studies were evaluated 24 h after PD administration. Results of the present study revealed that rats intoxicated with PD induced- oxidative stress and inflammation via an increase in malondialdehyde (MDA) and a decrease in nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway and glutathione (GSH) levels with an increase in brain contents of tumor necrosis factor-alpha (TNF-α) and interleukin (IL-6). Pre-treatment with TNG (100 mg/kg; orally) ameliorated behavior, cholinergic activities, and oxidative stress and decreased the elevated levels of pro-inflammatory mediators; TNF-α and IL-6 with a decrease in brain content of chromium residues detected by Plasma–Optical Emission Spectrometer. Also, the histopathological picture of the brain was improved significantly in rats that received TNG (100 mg/kg). Additionally, TNG decreased caspase-3 expression in the brain of PD rats. In conclusion, TNG possesses a significant neuroprotective role against PD-induced acute brain injury via modulating the Nrf2 signaling pathway and quenching the release of inflammatory mediators and apoptosis in rats.

Biography:

Khaled Alsubari is an expert in evaluation with a strong passion for improving health and wellbeing. He has developed an open and contextual evaluation model based on responsive constructivism, creating new avenues for enhancing healthcare. This model is built upon years of experience in research, evaluation, teaching, and administration, both in hospitals and educational institutions worked as a supervisor in a pharmaceutical and medical drugs company, where he gained extensive experience in the field of medications, their development, and marketing. He also has significant expertise in patient care within hospitals. His comprehensive background in both the pharmaceutical industry and healthcare has equipped him with a unique understanding of drug management and patient treatment strategies.

Abstract:

Traditional medicine has historically utilized herbs of different kinds to treat a wide range of illnesses. The use of remedies derived from plants as a replacement for synthetic chemicals has received a lot of attention in modern times. While Cichorium intybus is frequently used in traditional medicine to treat various conditions, not enough research has been done to confirm its anti-oxidant and anti-inflammatory effect

Objectives: The current study aims to evaluate the antioxidant and anti-inflammatory activities of the plant’s seed methanolic extract

Methodology: Maceration was used for getting the plant seed's methanolic extract. The sample underwent a physicochemical analysis in accordance with USP, 2016 requirements. The primary and secondary metabolites were evaluated both qualitatively and quantitatively in accordance with established protocols. The in vitro anti-inflammatory activity was investigated using the protein denaturation method, with diclofenac serving as the standard. To assess the anti-oxidant effect, phosphomilybednum, hydrogen peroxide scavenging assays, DPPH, and FRAP were used. The standard for antioxidant activity was vitamin C.

Biography:

Amir Ali Jalili Manesh is a student of pharmacology in Shahid Beheshti University, based in Tehran. His interest in drug efficacy and side effects made him to investigate in purpose of improving health care system. He intends to put his academic knowledge into practice and turn theory to practical knowledge. He has interest in clinical pharmacy and pharmaco therapeutics and his ultimate goal is to work with doctors to ensure the optimal patient care. One of the goals of him is to cooperate with international congresses on pharmacology for drug discovery and development.

Abstract:

Introduction: Controlled hypotension during surgical procedure is a way to decrease blood pressure and subsequently, improve field of operation. Clonidine is an antihypertensive agent used for induced hypotension. Correction of maxillomandibular discrepancies may need to perform osteotomy on both jaws in many cases which is associated with significant blood loss.

Material and Methods: 30 participants candidate to double-jaw orthognathic surgery were classified into two groups with equal number. In one group, 300microgram oral clonidine premedication, 90 minutes before operation and in the other group a placebo with the same condition as group 1 were administered. Mean arterial pressure (MAP) and heart rate in 10 minutes interval, operation time, blood loss and surgeon's satisfaction were measured.

Results: 10 men and 5 women with the mean age of 22.9 ± 2.9 in study group and 13 men and 2 women with the mean age of 22.1± 2.1 in control group were evaluated. The MAP was significantly lower in clonidine group (P value <0.001). Intra-operative bleeding was 508.67±  46.2 milliliter (mL) in placebo group and 287.33±72.06mL in clonidine group and the difference was statistically significant (P <0.05). Significant differences were observed in operation time (P <0.05) and surgeon's satisfaction (P<0.001).

Conclusion: The authors of this study suggest clonidine premedication in bimaxillary orthognathic surgery. Hemodynamic stability, bleeding control, decreasing the operation time and enhancing the surgical results are advantages of this method.

Biography:

Gang-Min Hur currently holds the position of Chair Professor in the Department of Pharmacology at the College of Medicine, Chungnam National University. Additionally, he serves as a project manager at the National Research Foundation (NRF) of Korea. He completed his post-doctoral research at the National Cancer Institute, National Institute of Health, USA. He earned his PhD and Bachelor of Medicine degrees from Chungnam National University, Korea and has been recognized with several academic and scientific awards. His research focuses on cell death signaling pathways in cancer, the role of reactive oxygen species and oxidative stress in these pathways (including apoptotic and necroptotic cell death), and the investigation of natural products as potential anti-cancer agents.

Abstract:

Receptor interacting protein 1 (RIP1) has emerged as a key molecular switch in inducing necroptosis, an alternative programmed cell death mode that can overcome apoptosis resistance in cancer therapy. Therefore, discovering a substance that modulates the cytotoxic potential of RIP1 may provide an effective strategy to bypass apoptosis resistance in cancer chemotherapeutics. In this study, it was found that rubianol-B, a triterpenoids purified from Rubia phillippinesis, promoted RIP1-dependent apoptosis via caspase-8 activation in multiple types of human cancer cells. Interestingly, pharmacological or genetic inhibition of caspase-8 was sufficient to switch the cell death mode from apoptosis to necroptosis following rubianol-B treatment, through necrosome formation in RIPK3-expressing human colorectal cancer (CRC) cells, accompanied by the upregulation of cytotoxic potential of RIP1 phosphorylation. Conversely, rubianol-B-induced cell death was almost completely abrogated by RIPK deficiency. The enhanced RIP1 phosphorylation and necroptosis triggered by rubianol-B treatment occurred independently of tumor necrosis factor receptor signaling, and was mediated by the production of reactive oxygen species via NADPH oxidase 1 in CRC cells. Thus, it is proposed that rubianol-B is a novel anticancer agent that enhances the cytotoxic potential of RIP1, warranting further development of rubianol-B as a necroptosis-targeting compound in apoptosis-resistant CRC

Biography:

Gurpreet Singh is currently the Vice President, Managing Director Integrated Safety at IQVIA. He is based in UK and has a total of 19 years' experience in Pharma Industry of which 17+ years have been in Global Drug Development. During these years he has had the opportunity to work with some top Global companies like Cognizant, Tata Consultancy, Novartis and Parexel. At Novartis he was the Global Head of PV Operations managing all Global PV activities. At Parexel he was the Senior Director PV Operations responsible for managing PV projects of top Global Pharma and Biotech companies. Gurpreet is a certified Six Sigma and Project Management Professional. He has keen interest in Digital Transformation and Organization Culture and has successfully led various projects during his tenure in the Pharma Industry. He is an avid runner and a speaker at various Pharma conferences.

Abstract:

The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over $1 billion. Global Top Pharmaceutical Companies based on projected R&D spending in 2026 are Roche, Johnson & Johnson, Merck & Co, Pfizer and Novartis. The global CRO services market in terms of revenue was estimated to be worth $76.6 billion in 2023 and is poised to reach $127.3 billion by 2028

Global Drug Development Trends

• Increased Focus on Quality, Compliance and Quality Management System
• Requirements of Audit and Inspection readiness
• Process Enhancements, Changes, Improvements
• Further adoption of Technology and Tools, Database migrations
• Focus on Data Analytics and Trends
• Organisational Culture Enhancement –Focus on People Development, Training and Retention
• Change Management – Mergers / Acquisitions and Integrations

Biography:

Compassionate and systematic pharmaceutical professional with two years of experience in pharmaceutical services, possessing a strong foundation in clinical pharmacology. Known for a solid track record in delivering impactful community health education programs and recognized for both clinical expertise and technical acumen. Completed a Bachelor’s degree in Pharmacy on January 31, 2024, at the Faculty of Pharmacy, Tartous University, Syria. Currently pursuing fully-funded scholarship opportunities to advance to a Master’s degree.

Abstract:

The part of sexuality in pharmacology research was not acknowledged, and it was not thought-out to be a determinant that could impact strength and disease. For decades research has mainly contained male, women and animals, leading to a lack of news about syndromes in females. Still, it is critical to guarantee equal likeness so that determine the security, influence, and resistance of healing agents for all individuals. The underrepresentation of female models in preclinical studies over various decades has surpassed to disparities in the understanding, disease, and treatment of ailments 'tween genders. The closeness of sexuality bias has happened recognized as a contributing determinant to the restricted interpretation and replicability of preclinical research. Many demands operation have stressed the significance of including sexuality as a organic changeable, and this view is acquire growing support. Regardless of important progress in incorporating more female models into preclinical studies, differences prevail contemporary. The current review focuses on the part of sexuality and common in biomedical research and, therefore, their potential function in pharmacology and analyze the potential risks guide.

Biography:

Dr Owen Underwood has a PhD from the University of Nottingham in the molecular signalling and dynamics of the Mu-opioid receptor and has joined the team at Z7 Biotech as a Senior Scientist. He has expertise in assay and technology development with a focus on GPCRs and 8 years molecular pharmacology experience. Z7 Biotech is a precision pharmacology Contract Research Organisation with a specialty in difficult early-stage drug discovery, working with both larger and small pharma and biotech.

Abstract:

GPCRs are large in both number and their portion of approved drug targets. However, studying these proteins biophysically has been made all the more difficult by their membrane environment. Most methods of biophysical study rely on lengthy purification steps of large volumes of protein, separated from their lipid environment and the large number of associated molecules that inhabit this cellular fraction. Drug discovery requires higher throughput tools that work without purification, however, are sensitive to small changes in the GPCR systems. We developed ThermoBRET™ and its associated technology, ModuMelt™, to detect GPCR stabilisation by both orthosteric and allosteric ligands. We can use these technologies to report ligand affinity without the need for protein purification or known ligands. We can take this a step further, using identified ligands to assess the effect of allosteric ligands on orthosteric ligand affinity, in a manner that can identify dependency of the allosteric ligand on the orthosteric ligand chosen. Similarly, we have developed SolThermoBRET, a method of applying similar principles to soluble proteins, allowing the detection of ligands and binders. Once complete we can take the study of target receptors and compounds forward into more detail pharmacology, using BRET-based biosensors to more.